Interní Med. 2007; 9(7): 334-337

PANCREATIC MALDIGESTION

prof. MUDr. Přemysl Frič DrSc
Interní klinika 1. LF UK a Ústřední vojenské nemocnice, subkatedra gastroenterologie IPVZ, Praha

The causes of pancreatic maldigestion include decreased exocrine pancreatic secretion, altered synchronization of digestion in the upper digestive tube, and decreased digestive potency of pancreatic enzymes in the small intestine. Maldigestion affects basic foodstuffs, liposoluble vitamins, calcium, and cobalamin. Functional diagnostics are limited at present to indirect tests (pancreatic enzymes in stools and 13C-breath test with mixed triglyceride). Therapy includes mainly dietary regimen and pancreatin replacement therapy. All available preparations (minimicrospheresTM, minitablets, and usual size tablets) are enterosolvent. The digestive potency of minimicrospheres is higher in comparison with larger particles. Replacement therapy is indicated with decreased body mass and complaints in relation to steatorhea. Treatment failure requires a systematic approach to find its cause. Adequate replacement therapy improves not only maldigestion, but it may influence to a certain extent pancreatic pain as well as synthesis and secretion of some gastrointestinal hormones. Undesired side effects of pancreatin are infrequent.

Keywords: pancreatic maldigestion, pathophysiology, diagnostics, enzymes, replacement therapy

Published: December 18, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Frič P. PANCREATIC MALDIGESTION. Interní Med. 2007;9(7):334-337.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ammann ST, Bishop M, Curington C, Toskes PP. Fecal pancreatic elastase 1 is inaccurate in the diagnosis of chronic pancreatitis. Pancreas 1996; 13: 226-230. Go to original source... Go to PubMed...
    2. Andersen JR, Bendtsen F, Ovesen L, et al. Pancreatic insufficiency. Duodenal and jejunal pH, bile acid activity, and micellar lipid solubilization. Int J Pancreatol 1990; 6: 263-270. Go to original source... Go to PubMed...
    3. Arendt T, Fölsch UR. Treatment of pancreatic exocrine dysfunction. In: Büchler MW, Friess H, Uhl W, Malfertheiner P: Chronic pancreatitis. Novel concepts in biology and therapy. Blackwell, Oxford, 2002: 395-402.
    4. Bovo P, Cataudella G, DiFrancesco V, et al. Intraluminal gastric pH in chronic pancreatitis. Gut 1995; 36: 294-298. Go to original source... Go to PubMed...
    5. Bruno MJ. Treatment of exocrine pancreatic insufficiency in chronic pancreatitis. In: Lankisch PG, DiMagno EP (vyd): Pancreatic Disease. State of the Art and Future Aspects of Research. Springer, Berlin, 1998: 121-131. Go to original source...
    6. Caliari S, Benini L Sembenini C, et al. Medium-chain triglyceride absorption in patients with pancreatic insufficiency. Scand J Gastroenterol 1996; 31: 90-94. Go to original source... Go to PubMed...
    7. Carriere F, Barrowman JA, Verger R, Laugier R. Secretion and contribution to lipolysis of gastric and pancreatic lipases during a test meal in humans. Gastroenterology 1993; 105: 876-888. Go to original source... Go to PubMed...
    8. DiMagno EP. Exocrine pancreatic insufficiency: current and future treatment. In: Büchler MW, Friess H, Uhl W, Malfertheiner P: Chronic pancreatitis. Novel concepts in biology and therapy. Blackwell, Oxford, 2002: 403-408.
    9. Dutta SK, Hlasko J. Dietary fiber in pancreatic disease: effect of high fiber diet on fat malabsorption in pancreatic insufficiency and in vitro study of the interaction of dietary fiber with pancreatic enzymes. Am J Clin Nutr 1985; 41: 517-525. Go to original source... Go to PubMed...
    10. FitzSimmons SC, Burkhart GA, Borowitz D, et al. High-dose pancreatic enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med 1997; 336: 1283-1289. Go to original source... Go to PubMed...
    11. Gullo L, Graziano L, Rabbini S, Battistini A. Fecal elastase in children with cystic fibrosis. Eur J Pediat 1997; 156: 770-772. Go to original source... Go to PubMed...
    12. Gullo L, Stella A, Labriola E, et al. Cardiovascular lesions in chronic pancreatitis: a prospective study. Dig Dis Sci 1982; 27: 716-722. Go to original source... Go to PubMed...
    13. Gullo L, Tassoni U, Mazzoni G, Stefanini F. Increased prevalence of aortic calcification in chronic pancreatitis. Am J Gastroenterol 1996; 91: 759-761.
    14. Hamwi A, Veitl M, Maenner G, et al. Pancreatic elastase 1 in stool; variations with one stool passage and individual changes from day to day. Wien Klin Wschr 2000; 112: 32-35.
    15. Hendeles L, Dorf A, Stecenko A, Weiberger M. Treatment failure after substitution of generic pancreolipase capsules. Correlation with in vitro lipase activity. JAMA 1990; 263: 2459-2461. Go to original source...
    16. Jain NK, Boivin M, Zinsmeister AR, DiMagno EP. The ileum and carbohydrate mediated feedback regulation of postprandial pancreatobiliary secretion in normal humans. Pancreas 1991; 6: 495-505. Go to original source... Go to PubMed...
    17. Katschinski M, Schirra J, Bross A, et al. Duodenal secretion and fecal excretion of pancreatic elastase 1 in healthy humans and patients with chronic pancreatitis. Pancreas 1997; 15: 191-200. Go to original source... Go to PubMed...
    18. Kocna P: Dechové testy - moderní neinvazivní diagnostika. Interní Med 2006; 7: 336-341.
    19. Kocna P, Vaníčková Z, Krechler T, et al. Testy exokrinní funkce pankreatu - elastáza-1 a dechový test s 13C-MTG. Bulletin HPB 2006; 14: 97-99.
    20. Kühnelt P, Mundlos S, Adler G. Einfluss der Pelletgrösse eines Pankreasenzympräparates auf die duodenale lipolytische Aktivität. Z Gastroenterol 1991; 29: 417-421. Go to PubMed...
    21. Lankisch PG, Ehrhardt-Schmelzer S: Die Chymotrypsinbestimmung im Stuhl: ein indirekter Pankreasfunktionstest. Dtsch Med Wschr 1984; 109: 1527-1529. Go to original source... Go to PubMed...
    22. Lankisch PG, Schmidt I, König H, et al. Fecal elastase 1: not helpful in diagnosing chronic pancreatitis associated with mild to moderate exocrine pancreatic insufficiency. Gut 1998; 42: 551-554. Go to original source... Go to PubMed...
    23. Layer P, Go VLW, DiMagno EP. Fate of pancreatic enzymes during aboral small intestinal transit in humans. Am J Physiol 1986; 251: G475-480. Go to original source... Go to PubMed...
    24. Layer P, von der Ohe MR, Holst JJ, et al. Altered postprandial motility in chronic pancreatitis: role of malabsorption. Gastroenterology 1997; 112: 1624-1634. Go to original source... Go to PubMed...
    25. Layer P, Zinsmeister AR, DiMagno EP. Effects of decreasing intraluminal amylase activity on starch digestion and postprandial gastrointestinal function in humans. Gastroenterology 1986; 91: 41-48. Go to original source... Go to PubMed...
    26. Löser C, Mollgaard A, Fölsch UR. Fecal elastase 1: a novel, highly sensitive, and specific tubeless pancreatic function test. Gut 1996; 39: 580-586. Go to original source... Go to PubMed...
    27. Malfertheiner P, Dominguez-Muňoz JE. Effect of exogenous pancreatic enzymes on gastrointestinal and pancreatic hormone release and gastrointestinal motility. Digestion 1993; 54 (Suppl 2): 15-20. Go to original source... Go to PubMed...
    28. Mališ F, Frič P. In-vitro-Analyse der zur Pankreasenzym-Substitutionstherapie angewandter Substanzen. Arzneim-Forsch (Drug Research) 1974; 24: 499-504.
    29. Marcoullis G, Parmentier Y, Nicolas J-P. et al. Cobalamin malabsorption due to nondegradation of R proteins in the human intestine. J clin Invest 1980; 66: 430-440. Go to original source... Go to PubMed...
    30. Meyer JH, Elashoff J, Porter-Fink V, et al. Human postprandial gastric emptying of 1-3 millimeter spheres. Gastroenterology 1988; 94: 1315-1325. Go to original source... Go to PubMed...
    31. Montalto G, Soresi M, Carroccio A, et al. Lipoproteins and chronic pancreatitis. Pancreas 1994; 9: 137-138. Go to original source... Go to PubMed...
    32. Rämö OJ, Puolakkeinen PA, Seppälä K, Schröder TM. Self-administration of enzyme substitution in the treatment of exocrine pancreatic insufficiency. Scand J Gastroenterol 1989; 24: 688-692. Go to original source... Go to PubMed...
    33. Smyth RL, van Velzen D, Smyth AR, et al. Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes. Lancet 1994; 343: 85-86. Go to original source... Go to PubMed...
    34. Toskes PP. Current concepts of cobalamin (vitamin B12) absorption and malabsorption. J Clin Gastroenterol 1980; 2: 287-297. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.